Ionis Poised To Build Out Commercial Portfolio With Donidalorsen Success
A Phase III study testing the ligand-conjugated anti-sense medicine in hereditary angioedema read out positively, but the drug would join a competitive market if approved.
A Phase III study testing the ligand-conjugated anti-sense medicine in hereditary angioedema read out positively, but the drug would join a competitive market if approved.